• By ICR Secretariat
• Posted Wednesday, July 12, 2023

With FDA approval in hand, BioMarin lays out plan to sell $2.9M gene therapy

https://www.biopharmadive.com/news/biomarin-roctavian-launch-hemophilia-a-gene-therapy-sale/654451/

BioMarin Pharmaceutical, having secured a long-awaited approval from the Food and Drug Administration, says its focus has now turned to launching its new hemophilia gene therapy in the U.S. market.